Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 479-940-2 | CAS number: 613246-75-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2005-01-25 - 2005-02-22
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 005
- Report date:
- 2005
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- July 27th 1995
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Version / remarks:
- July 30th 1996
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- -
- EC Number:
- 479-940-2
- EC Name:
- -
- Cas Number:
- 613246-75-6
- Molecular formula:
- NA: Multi-const. substance
- IUPAC Name:
- 16-(dodecanoyloxy)-2,2,5,8,12,15,15-heptamethyl-7,10-dioxa-4,13-diazahexadeca-3,13-dien-1-yl dodecanoate
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: CHARLES RIVER (EUROPE) LABORATORIES INC.
- Age at study initiation: 50 - 61 days
- Weight at study initiation: male: 232 - 257g; female: 184 - 209g
- Housing: Group caging (5 animals/cage); III. type polypropylene/polycarbonate
- Acclimation period: 13 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±3
- Humidity (%): 30 - 70
- Air changes (per hr): 12
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: sunflower oil
- Details on oral exposure:
- The test item was administered daily by gavage on a 7 days/week basis. Control animals were treated with vehicle only. Treatment volume was constant at 10 mL/kg bw throughout all groups. Actual treatment volume was calculated according to the most recent body weight. Animals were not treated on the day of gross pathology.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Doses were chosen based on a previous 14-day oral toxicity study with Sika Hardener LJ. Dosing solution concentrations were controlled on the first and last treatment day using GC methodology in the Analytical Laboratory of LAB International Hungary. Three parallel samples were taken from the upper, middle and lower layers of each treatment concentration and control at both sampling times (72 samples total). Sika Hardener LJ content in dosing formulations ranged from 100% to 108% of the nominal concentration and was distributed homogeneously in sunflower oil.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- The test item was administered daily by gavage on a 7 days/week basis.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 50 mg/kg bw/day (nominal)
- Dose / conc.:
- 250 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 5 animals per sex/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Doses were chosen based on a 14-day oral toxicity study with Sika Hardener LJ.
- Rationale for selecting satellite groups: no satellite groups. - Positive control:
- No
Examinations
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once a day
- observation sites: skin, fur, eyes and mucous membranes, respiratory, circulatory, autonomic and central nervous system, somatomotor activity and behaviour pattern
BODY WEIGHT: Yes
- Time schedule for examinations: recorded on day 0, then weekly.
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: before treatment and in week 4
- Dose groups that were examined: before treatment all test animals were examined. Examination in control group and group 4 on week 4.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: one day after the last treatment by heart puncture
- Anaesthetic used for blood collection: Yes, pentobarbital (Nembutal) anaesthesia
- Animals fasted: Yes, overnight before blood sampling
- How many animals: all animals
- Parameters checked are as follows: RBC (Red Blood Cell count), WBC (White Blood Cell count), Hgb (Haemoglobin concentration), Htc (Haematocrit; relative volume of erythrocytes), MCV (Mean Corpuscular (erythrocyte) Volume), MCH (Mean Corpuscular (erythrocyte) Haemoglobin), MCHC (Mean Corpuscular (erythrocyte) Haemoglobin Concentration) Plt (Platelet (thrombocyte) count), PTT (Partial Thromboplastin Time), PT (Prothrombin Time), Differential white blood cell count, Reticulocytes.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: one day after the last treatment by heart puncture
- Animals fasted: Yes, overnight.
- How many animals: all animals
- Parameters checked are as follows Glucose, T-BIL, Urea Nitrogen, Chol., Creat. Phos., Na+, K+, Ca++, Cl-, Total Protein, Albumin, A/G, AST/GOT, ALT/GPT, ALP, GGT
URINALYSIS: Yes
- Time schedule for collection of urine: Samples were collected over a period of 16 h from all animals on week 4
- Animals fasted: No
- Parameters checked are as follows: Leukocytes, Nitrite, pH, Protein, Glucose, UBG, Bilirubin, Ketone, Blood, Spec. gravity, Sediment, Volume.
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: once before first exposure and in the fourth exposure week
- Dose groups that were examined: all animals
- Battery of functions tested: sensory reactivity to stimuli of different types (auditory, visual and proprioceptive), grip strength and motor activity - Sacrifice and pathology:
- Gross pathology was performed on every animal after terminating treatment (one day after last dosing). Animals were sacrificed under pentobarbital (Euthanyl) anaesthesia. After exsanguination external appearance was examined, cranium, thoracic and abdominal cavities were opened and the appearance of tissues and organs were abserved macroscopically. Any abnormality was recorded with details of the location. colour, shape and size. The following organs/tissues were removed and preserved in 10% buffered formaldehyde solution:
Gross lesions, lymph nodes (submandibular, mesenteric), sternum, skin and female mammary gland, salivary glands (submandibular), femur and bone marrow, spinal cord (cervical, lumbar, thoracic level), pituitary, thymus, trachea, lungs (with main stem bronchi), heart, thyroid and parathyroid, oesophagus, stomach, small and large intestines including Peyer´s patches (duodenum, ileum, jejunum, caecum, colon, rectum), urinary bladder, liver, pancreas, spleen, kidneys, adrenals, prostate, testes with epididymides, ovaries, uterus with vagina, brain (including cerebrum, cerebellum and ponds), eyes with optic nerve, Harderian glands and lachrymal gland, seminal vesicle, muscle (quadriceps), sciatic nerve and aorta
Histopathology was performed on preserved organs and tissues of the control group and group 4 animals. Groups 2 and 3 showed no undiagnosed gross lesions at necropsy, so organs were not examined histologically.
The following organs were weighed and recorded:
With precision of 0.01 g: liver, kidneys (left + right), testes (left + right), epididymides (left + right), thymus, spleen, brain, heart
With precision of 0.001 g: adrenals (left + right) - Statistics:
- Statistical analysis was done with SPSS PC software for the following data:
- body weight
- haematology
- clinical chemistry
- urine
- organ weight
The heterogeneity of variance between groups was checked by Bartlett´s homogeneity of variance test. Where no significant heterogeneity is detected, a one-way analysis of variance was carried out. If the obtained result was positive, Duncan´s Multiple Range test was used to assess the significance of inter-group differences.
Where significant heterogeneity was found, the normal distribution of data was examined by Kolmogorov-Smirnov test. In case of a not normal distribution, the non parametric method of Kruskal-Wallis one-way analysis of variance was applied. If there was a positive result, the inter-group comparisons were performed using Mann-Whitney U-test.
Frequency of toxic response, pathological and histopathological findings by sex and dose was calculated.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
No mortality or clinical symptoms occured during the observation period. The behaviour, general state and reactivity to different types of stimuli of all animals were normal during the 28-day treatment period.
BODY WEIGHT AND WEIGHT GAIN
The body weight development was undisturbed during the 28 days. The mean body weight and the body weight gain were similar in all experimental groups and was similar to the expected values in untreated animals of the same age and strain.
OPHTHALMOSCOPIC EXAMINATION
No eye alterations were recorded at the end of the treatment period. The adnexa, conjunctiva, cornea, lens, vitrous body and fundus of eyes were intact in the control and high dose treated animals.
HAEMATOLOGY
Examined haematological parameters were comparable in control and treatment groups.
CLINICAL CHEMISTRY
Clinical chemistry revealed no biologically significant changes in parameters examined, even though some findings in treatment groups were statistically different when compared to the control group. No clear dose-response relationship was found and the degree of change was within the normal physiological range (and within historical control ranges), specific for animals of this species and strain with the same age.
Creatinine concentration (50mg/kg bw/day and 1000 mg/kg bw/day, male) and aspartate aminotransferase activity (1000 mg/kg bw/day, male) were decreased compared to control values. Sodium (50mg/kg bw/day and 1000 mg/kg bw/day, female), chloride (250mg/kg bw/day and 1000 mg/kg bw/day male, 50 mg/kg bw/day female), calcium (all dosed groups) and phosphorous (50 mg/kg bw/day, female) levels exceeded appropriate control values. Increased alanin aminotransferase activity was recorded for the male 250 mg/kg bw/day group. Total protein (1000 mg/kg bw/day) and albumin (50mg/kg bw/day, 1000 mg/kg bw/day) concentrations increased in female groups. The A/G ratio increased in both sexes ( 1000mg/kg bw/day male and 50 mg/kg bw/day female), due to the slight increase in albumin concentration.
URINALYSIS
Urine parameters varied within the normal (historical control) range. Control and treatment groups were not significantly different
NEUROBEHAVIOUR
The behaviour, general state and reactivity to different types of stimuli of all animals were normal during the 28-day treatment period.
ORGAN WEIGHTS
Spleen weight (absolute and referred to the body and brain weight) in group 4 (males) was statistically significant decreased when compared to the control group but were within the historical control range. Thus, changes in spleen weight were not considered biologically significant.Kidney weight referred to the brain weight, but not relative to the body weight or absolute kidney weight was statistically significant different in group 3 (males) compared to control animals. No dose dependent reduction in kidney weight was observed and the data was within the historical range. No statistically significant differences in organ weight were recorded for female groups. Clinical pathology, gross pathology and histopathology did not confirm treatment related effects. None of the statistically significant findings were indicative of treatment related adverse effects, but considered to be the result of biological variation.
GROSS PATHOLOGY
Gross pathology did not reveal macroscopic alterations related to treatment.
Pulmonary emphysema, point-like and pinprick-sized haemorrhages in the lungs were observed in the control and treated group. These alterations were caused by the termination procedures and exsanguination.
Pyelectasis occurred in one male animal. Taking into account the low incidence of this alteration and historical control data, pyelectasis has no toxicological significance in this study.
Hydrometra due to the sexual cycle was detected in one female rat.
HISTOPATHOLOGY: NON-NEOPLASTIC
Histological examination of organs detected no lesions attributable to treatment. Observed changes were of equal frequency comparing control and group 4 animals (1000mg/kg bw/day) or were judged specific for species and strain of equal age.
The alveolar emphysema and focal haemorrhage in the lungs recorded for control and group 4 animals were considered a consequence of hypoxia, dyspnoea and circulatory disturbance developed during exsanguination.
Pyelectasis (one side) in the kidney occurred only in one mal animal without degenerative, inflammatory or fibrotic lesions in the renal tissues. This is a common disorder found in experimental rats of this strain.
The focal proliferation of cells belonging to the mononuclear phagocyte system (MPS) and focal vacuolisation of hepatocytes in the liver occurred in comparable incidences in control and group 4. Thus, these alterations were not considered to be of toxicological significance.
The dilatation of the uterine horn in one female animal is an individual slight neuro-hormonal phenomenon in connection with the sexual function of the inner genital organs. This finding is not considered to be relevant taking into consideration of historical control.
Effect levels
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects observed.
Target system / organ toxicity
- Key result
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Sika Hardener LJ caused no toxic effects in male and female CRL:(WI)BR rats after consecutive 28-day oral (gavage) administration of 50 mg/kg bw/day, 250 mg/kg bw/day and 1000 mg/kg bw/day doses. Therefore the No Observed Effect Level (NOEL) is 1000 mg/kg bw/day.
- Executive summary:
Sika Hardener LJ was tested for repeated dose toxicity in a 28 day oral gavage test according to OECD guideline 407 and EU method B.7. Sika Hardener LJ was administered to CRL:(WI)BR rats (n=5/sex/dose) at dose levels of 0 mg/kg bw/day (vehicle only, control), 50 mg/kg bw/day, 250 mg/kg bw/day and 1000 mg/kg bw/day orally for 28 consecutive days. The stability and accurateness of concentrations of dosing solutions were analytically proven. Solutions were stable at room temperature for 4 hours and at 5±3 °C for 5 days. Test item content in dosing formulation samples ranged between 100 % and 108 % of nominal concentrations and was distributed homogeneously. Individual clinical observations were made on all animals daily. Detailed clinical observations were made outside the home cage on all animals once, prior to the first exposure and once on week 4. Body weight and food consumption were measured weekly. Blood and urine sampling for clinical pathology and gross pathology were conducted at the end of the treatment period. Selected organs were weighed. Histological examination was performed on the preserved organs or tissues of group 1 (control) and group 4 (1000 mg/kg bw/day).
Results were interpreted comparing treatment groups to the control group. The control group was treated in a similar way compared to treatment groups, but test compound was omitted and only vehicle (sunflower oil) administered.
No mortality or clinical symptoms were recorded during the 28-day treatment period. The general state, behaviour and reaction to different types of stimuli were similar in control and experimental groups.
The body weight, body weight gain and the mean daily food intake were comparable in control and experimental groups.
No eye alterations were recorded at the end of the treatment period.
Dosing animals with test item did not influence clinical pathology parameters. The slight changes in creatinine, sodium, chloride, calcium, phosphorous, total protein and albumin concentrations, in AST and ALT activity, in A/G ratio were within the physiological range and were judged to be without toxicological significance.
Pulmonary emphysema, point-like and pinprick-sized haemorrhages in the lungs (due to the termination procedures), pyelectasis and hydrometra (common alterations specific in experimental rats) were recorded in gross pathology. These findings were without toxicological significance as they were observed in comparable frequency between groups or in single animals only.
In group 4 (males, 1000 mg/kg bw/day), spleen weight was statistically significantly decreased on an absolute and relative basis compared to control animals, but within the historical control range. Kidney weight, relative to brain weight, was statistically significantly different in group 3 (250 mg/kg bw/day) animals when compared to control animals, but was within the historical control range. Clinical chemistry, gross pathology and histopathology do not support the conclusion of a treatment related effect with respect to organ weight. Overall, none of the statistically significant findings were indicative of treatment related adverse effects, but considered to be the result of biological variation.
In organs subjected to histopathological examination no test item related lesions were recorded. None of the histopathological findings were dose dependent. Alveolar emphysema and focal haemorrhage in the lungs (consequence of hypoxia, dyspnoea and circulatory disturbance developed during exsanguination), pyelectasis without degenerative, inflammatory or fibrotic lesions in the renal tissues (common alteration in this species), focal proliferation of cells belonging to the mononuclear phagocyte system (MPS) in the liver, focal vacuolisation of hepatocytes, (occurred in control group and in group 4 with similar frequency), dilatation of the uterine horns (due to the sexual function of the inner genital organs) were observed. These alterations are specific for this species, and are therefore not considered toxicologically significant.
The study was marked as reliable without restrictions. The No Observed Effect Level (NOEL) 1000 was mg/kg bw/day. (LAB, 2005)
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.